Group 1 - FDC Ltd has received ANDA approval from the US FDA for Pilocarpine Hydrochloride Ophthalmic Solution in concentrations of 1%, 2%, and 4% [1] - Apollo Hospitals Enterprise has acquired 8.5 million equity shares of Apollo Gleneagles PET-CT, making it a wholly-owned subsidiary [2] - Bajaj Healthcare has received a positive recommendation from the SEC to initiate Phase III clinical trials for Suvorexant tablets, becoming the first in India to receive regulatory approval for this insomnia treatment [3] Group 2 - AstraZeneca Pharma India has been granted permission to import Trastuzumab Deruxtecan for sale and distribution [4] - Torrent Pharmaceuticals has received demand notices exceeding ₹6.63 crore from the NPPA for alleged overcharging on five drugs from January 2016 to November 2018 [5] - The US FDA issued a Form-483 with four observations after inspecting Lupin's Pithampur Unit-2, classifying the inspection as 'Official Action Indicated' [6] Group 3 - The stalled open offer for a 26.1% stake in Fortis Healthcare by IHH Healthcare has been approved by SEBI, allowing IHH to proceed with the offer after seven years [7]

WCLC 2025 Highlights DAIICHI SANKYO CO., LTD. September 17th (US)/ 18th (JP), 2025 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are vario ...